This is the authors' abstract. We don't add key points for this paper.
Duchenne muscular dystrophy (DMD) is a recessive X-linked disease, a progressive and incurable disease that primarily affects the skeletal muscles. The dystrophin, a structural protein that is related to stabilization of muscle contraction is absent or altered in DMD. Patients with this dystrophy exhibit muscle wasting, impairing the ability to run, jump and climb ladders, culminating in a confinement to a wheelchair, on average 12 years old. Due to inactivity and immobility of the respiratory muscles, these patients will die due to respiratory complications. Several therapeutic strategies have been studied to improve the quality of life of these patients and their prognostics. The present study consists of a literature review, covering the main aspects of pathology and pointing out some of the different therapeutic strategies.
No takes yet. Share an insight, caveat, or question.
Carvalho et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: